Biological therapies have become commonly available for the treatment of rheumatoid arthritis (RA) over the past decades.[1] Biologics are considered in RA patients with active disease in spite of treatment with synthetic disease-modifying antirheumatic drugs (DMARDs), including methotrexate (MTX).[2] Tumor necrosis factor (TNF) inhibitors,[3–7] rituximab (a B cell depleting anti-CD20 antibody),[5] abatacept (a selective T cell co-stimulation modulator),[8] and tocilizumab (an anti-interleukin (IL) 6 receptor antibody),[9] have been approved for the treatment of RA. Here, TNF is linked to rheumatoid arthritis.